TrialBlood2015

Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma.

Ajay K Gopal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.